Two more Vioxx victories for Merck

Share this article:
Merck was awarded one federal and one state court victory related to Vioxx last week. Alabama state court jurors ruled in Merck’s favor Friday, rejecting the claims of a plaintiff who blamed the drugmaker’s withdrawn painkiller Vioxx for his heart attack in 2001. On Wednesday, a federal court in New Orleans also ruled in favor of Merck. “Juries continue to determine that Merck acted responsibly in its research of Vioxx and provided the appropriate information about Vioxx to patients and the medical community,” Merck EVP and general counsel Kenneth Frazier said in a statement. Attorneys for the plaintiff in the Alabama case argued that 57-year-old Gary Albright should receive as much as $5.75 million in his lawsuit filed last year. But jurors speaking with attorneys and reporters in the courtroom after the verdict said Albright had too many health problems before his heart attack to blame Vioxx. In a separate case, a federal jury in New Orleans last Wednesday ruled the drug maker adequately warned of the risks associated with the medicine. The lawsuit was filed by plaintiff Anthony Wayne Dedrick, 50, of Waynesboro, TN, who argued that his heart attack resulted from Merck failing to warn doctors adequately about the risk posed by taking the withdrawn painkiller Vioxx. Merck has won four federal cases involving Vioxx and lost one. In state courts, the drugmaker has won four cases and lost three. A case in New Jersey has been ordered to retrial after jurors sided with Merck.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.